Cambridge Cancer Compound Library

Cat.No.L2300

A unique collection of 242 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS).

Customize Your Library:

Specific Compounds
Quantities
96 or 384 well Plate Map
Dry/solid or DMSO solution

Cited by 334 Publications

Cambridge Cancer Compound Library Contents

Description & Advantages

• A highly value-added library derived through a collaboration with researchers at the MIT Koch Institute
• A unique collection of cancer-targeted compounds for high throughput screening (HTS) and high content screening (HCS)
• Embraces the whole spectrum of cancer targets, from kinases to notch signaling, to metabolic targets
• Structurally diverse, medicinally active and cell permeable
• Rich documentation with structure
• NMR and HPLC to ensure the high purity

Product Details

Formulation	242 compounds pre-dissolved in 10mM DMSO
Container	96 Deep Well Plate Sealed With Aluminum Foil
Stability	12 months	-20°C	in DMSO
Stability	24 months	-80°C	in DMSO
Shipping	Blue ice or dry ice

Case Studies using Selleck Compound Libraries

Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF=43) and took about 15 months):

Nature.2019;574(7777):268-272
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF=11) and took about 8 months):

Nat Commun. 2019 16;10(1):2197
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF=17) and took about 13 months):

Cell Res. 2019;29(9):739-753
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF=8) and took about 10 months):

Mov Disord. 2019;34(3):323-334
Application of Epigenetics Compound Library in acute lymphoblastic leukemia (This article was published in Blood (IF=16) and took about 16 months):

Blood. 2019 17;134(16):1323-1336
Application of Inhibitor Library in tumor immunology (This article was published in Cancer Immunol Res (IF=8.6) and took about 12 months):

Cancer Immunol Res.2017;5(9):790-803